{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T05:00:52Z","timestamp":1780290052407,"version":"3.54.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ejim.2026.106787","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T20:25:47Z","timestamp":1771878347000},"page":"106787","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Assessing the proportion of patients with type 2 diabetes in tertiary care eligible for combination therapy with GLP-1 receptor agonist and SGLT2 inhibitors"],"prefix":"10.1016","volume":"148","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4752-041X","authenticated-orcid":false,"given":"Anders B.","family":"Jensen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6053-298X","authenticated-orcid":false,"given":"Frida","family":"Renstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3228-0313","authenticated-orcid":false,"given":"Michael","family":"Br\u00e4ndle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2026.106787_bib0001","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1007\/s00125-022-05787-2","article-title":"Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD)","volume":"65","author":"Davies","year":"2022","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejim.2026.106787_bib0002","doi-asserted-by":"crossref","first-page":"S181","DOI":"10.2337\/dc25-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes\u20142025","volume":"48","author":"ElSayed","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejim.2026.106787_bib0003","doi-asserted-by":"crossref","DOI":"10.57187\/smw.2023.40060","article-title":"Swiss recommendations of the society for endocrinology and diabetes (SGED\/SSED) for the treatment of type 2 diabetes mellitus (2023)","volume":"153","author":"Gastaldi","year":"2023","journal-title":"Swiss Med Wkly"},{"key":"10.1016\/j.ejim.2026.106787_bib0004","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jcjd.2020.09.005","article-title":"Practical considerations and rationale for glucagon-like peptide-1 receptor agonist plus sodium-dependent glucose cotransporter-2 inhibitor combination therapy in type 2 diabetes","volume":"45","author":"Goldenberg","year":"2021","journal-title":"Can J Diabetes"},{"key":"10.1016\/j.ejim.2026.106787_bib0005","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s00125-025-06565-6","article-title":"Effectiveness and safety of combining SGLT2 inhibitors and GLP-1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis of cohort studies","volume":"69","author":"Colombijn","year":"2026","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejim.2026.106787_bib0006","unstructured":"Swiss Federal Office of Public Health (BAG). Spezialit\u00e4tenliste n.d. https:\/\/www.xn\u2013spezialittenliste-yqb.ch\/ShowPreparations.aspx (accessed November 25, 2025)."},{"key":"10.1016\/j.ejim.2026.106787_bib0007","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2017-000454","article-title":"Compliance with guidelines for disease management in diabetes: results from the SwissDiab Registry","volume":"6","author":"Schimke","year":"2018","journal-title":"BMJ Open Diab Res Care"},{"key":"10.1016\/j.ejim.2026.106787_bib0008","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2026.106787_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2024.111565","article-title":"Screening for heart failure in patients with diabetes mellitus in tertiary care \u2013 a SwissDiab study","volume":"209","author":"Knaus","year":"2024","journal-title":"Diabetes Res Clin Pr"},{"key":"10.1016\/j.ejim.2026.106787_bib0010","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.kint.2022.06.013","article-title":"Executive summary of the KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease: an update based on rapidly emerging new evidence","volume":"102","author":"Rossing","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.ejim.2026.106787_bib0011","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2026.106787_bib0012","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ejim.2026.106787_bib0013","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.2337\/dc19-2535","article-title":"Risk of major adverse cardiovascular events, severe hypoglycemia, and all-cause mortality for widely used antihyperglycemic dual and triple therapies for type 2 diabetes management: a cohort study of all Danish users","volume":"43","author":"Jensen","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejim.2026.106787_bib0014","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-078242","article-title":"Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study","author":"Simms-Williams","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.ejim.2026.106787_bib0015","doi-asserted-by":"crossref","DOI":"10.4414\/smw.2021.20525","article-title":"Representativeness of the Swiss diabetes registry \u2013 a single centre analysis","volume":"151","author":"Eichm\u00fcller","year":"2021","journal-title":"Swiss Med Wkly"},{"key":"10.1016\/j.ejim.2026.106787_bib0016","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2026.106787_bib0017","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2026.106787_bib0018","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2337\/dc08-1355","article-title":"Efficacy and safety comparison of liraglutide, glimepiride, and Placebo, all in combination with Metformin, in type 2 diabetes","volume":"32","author":"Nauck","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejim.2026.106787_bib0019","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.2337\/dc13-2759","article-title":"Efficacy and safety of Dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3)","volume":"37","author":"Umpierrez","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejim.2026.106787_bib0020","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","article-title":"Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial","volume":"5","author":"Sorli","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ejim.2026.106787_bib0021","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","article-title":"Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the global burden of disease study 2021","volume":"402","author":"Ong","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2026.106787_bib0022","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1007\/s40265-024-02090-9","article-title":"GLP-1 receptor agonists and SGLT2 inhibitors in type 2 diabetes: pleiotropic cardiometabolic effects and add-on value of a combined therapy","volume":"84","author":"Scheen","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.ejim.2026.106787_bib0023","article-title":"Discontinuation and reinitiation of SGLT-2 inhibitors and GLP-1R agonists in patients with type 2 diabetes: a nationwide study from 2013 to 2021","volume":"29","author":"Malik","year":"2023","journal-title":"Lancet Reg Health - Eur"},{"key":"10.1016\/j.ejim.2026.106787_bib0024","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/s41573-025-01183-8","article-title":"GLP-1-based therapies for diabetes, obesity and beyond","volume":"24","author":"Drucker","year":"2025","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ejim.2026.106787_bib0025","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus Semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2026.106787_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2023.100477","article-title":"Call to action: understanding the differences in the use of SGLT-2 inhibitors and GLP-1 receptor agonists","volume":"13","author":"Khedagi","year":"2023","journal-title":"Am J Prev Cardiol"},{"key":"10.1016\/j.ejim.2026.106787_bib0027","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1001\/jama.2024.27402","article-title":"Age and sex differences in efficacy of treatments for type 2 diabetes: a network meta-analysis","volume":"333","author":"Hanlon","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2026.106787_bib0028","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1007\/s00125-023-05891-x","article-title":"Sex differences in type 2 diabetes","volume":"66","author":"Kautzky-Willer","year":"2023","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejim.2026.106787_bib0029","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11906-015-0554-0","article-title":"Excess cardiovascular risk in diabetic women: a case for intensive treatment","volume":"17","author":"Recarti","year":"2015","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.ejim.2026.106787_bib0030","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1007\/s00125-023-05962-z","article-title":"Socioeconomic aspects of incretin-based therapy","volume":"66","author":"Karagiannis","year":"2023","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejim.2026.106787_bib0031","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1080\/03007995.2024.2303413","article-title":"Sociodemographic disparities in GLP-1RA and SGLT2i use among US adults with type 2 diabetes: NHANES 2005-March 2020","volume":"40","author":"Mittman","year":"2024","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ejim.2026.106787_bib0032","unstructured":"International price comparison. The Swedish dental and pharmaceutical benefits agency (TLV), www.tlv.se; 2024."}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620526000920?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620526000920?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T04:13:02Z","timestamp":1780287182000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620526000920"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":32,"alternative-id":["S0953620526000920"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2026.106787","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessing the proportion of patients with type 2 diabetes in tertiary care eligible for combination therapy with GLP-1 receptor agonist and SGLT2 inhibitors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2026.106787","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Federation of Internal Medicine.","name":"copyright","label":"Copyright"}],"article-number":"106787"}}